Isomorphic Labs reportedly in early talks to raise funds at a $40–50 billion valuation
Overview
Alphabet spinoff Isomorphic Labs is reportedly in early-stage talks to raise a new funding round at a valuation of $40 billion to $50 billion, according to Bloomberg, which did not specify the round's size.
The company, which develops AI drug-discovery software, earns revenue through research partnerships with Eli Lilly, Novartis and Johnson & Johnson. SiliconANGLE reports that the company claims its flagship platform, IsoDDE, is more than 50% better than the closest competing tool at binding pocket discovery and about 2.3 times better than AlphaFold at modeling antibody interactions; these performance claims are the company's own and have not been independently verified in the reporting.
Written by AI from the articles below · updated Oct 8, 7:47 PM ET
Check the sources:
Article timeline
Follow the coverage from different perspectives. Times are ET.
- SiliconANGLE · AIIsomorphic Labs reportedly raising funds at up to $50B valuation
AIAlphabet spinoff Isomorphic Labs is reportedly in early-stage talks to raise a new funding round at a valuation of $40 billion to $50 billion, according to Bloomberg, which did not specify the round's size. Isomorphic's flagship AI platform, IsoDDE, is designed to automate binding pocket discovery, which it says is more than 50% better than the closest competing tool, and it models antibody interactions about 2.3 times better than AlphaFold. The company earns revenue through research partnerships with Eli Lilly, Novartis and Johnson & Johnson.
Heat trend
Not enough continuous observations to show a trend yet.